As of 4:00pm ET
| +0.30 / +1.95%|
The 3 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 38.00, with a high estimate of 41.00 and a low estimate of 14.00. The median estimate represents a +142.81% increase from the last price of 15.65.
The current consensus among 4 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.